Biotech | February 17, 2022
Center for Breakthrough Medicines launches analytical testing
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Subscribe To Our Newsletter & Stay Updated
